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OBJECTIVE—Obesity and associated pathologies are major
global health problems. Transforming growth factor-b/Smad3 sig-
naling has been implicated in various metabolic processes, in-
cluding adipogenesis, insulin expression, and pancreatic b-cell
function. However, the systemic effects of Smad3 deﬁciency on
adiposity and insulin resistance in vivo remain elusive. This study
investigated the effects of Smad3 deﬁciency on whole-body glu-
cose and lipid homeostasis and its contribution to the develop-
ment of obesity and type 2 diabetes.
RESEARCH DESIGN ANDMETHODS—We compared various
metabolic proﬁles of Smad3-knockout and wild-type mice. We
also determined the mechanism by which Smad3 deﬁciency
affects the expression of genes involved in adipogenesis and
metabolism. Mice were then challenged with a high-fat diet to
study the impact of Smad3 deﬁciency on the development of
obesity and insulin resistance.
RESULTS—Smad3-knockout mice exhibited diminished adi-
posity with improved glucose tolerance and insulin sensitivity.
Chromatin immunoprecipitation assay revealed that Smad3 de-
ﬁciency increased CCAAT/enhancer-binding protein b-C/EBP
homologous protein 10 interaction and exerted a differential
regulation on proliferator-activated receptor b/d and prolifera-
tor-activated receptor g expression in adipocytes. Focused gene
expression proﬁling revealed an altered expression of genes
involved in adipogenesis, lipid accumulation, and fatty acid
b-oxidation, indicative of altered adipose physiology. Despite re-
duced physical activity with no modiﬁcation in food intake, these
mutant mice were resistant to obesity and insulin resistance in-
duced by a high-fat diet.
CONCLUSIONS—Smad3 is a multifaceted regulator in adipose
physiology and the pathogenesis of obesity and type 2 diabetes,
suggesting that Smad3 may be a potential target for the treatment
of obesity and its associated disorders. Diabetes 60:464–476,
2011
Obesity is a global medical issue by virtue of itsassociation with an array of metabolic abnor-malities, including insulin resistance, hyperten-sion, and hyperlipidemia, collectively termed
“metabolic syndrome” (1). Thus, the need is urgent for
elucidation of the molecular events underlying the devel-
opment of metabolic syndrome and for identiﬁcation of
novel targets for disease prevention and therapy.
Obesity is primarily characterized by increased fat mass
or white adipose tissue (WAT). WAT consists of adipo-
cytes specialized in the storage of fat (2). In addition to its
primary function as an energy reservoir, WAT is an endo-
crine organ that secretes adipocytokines (e.g., leptin and
resistin) that have been shown to regulate glucose and
lipid metabolism (3). In obesity, adipose secretion of adi-
pocytokines is disturbed. The mechanisms that underlie
obesity-associated pathologies, such as insulin resistance,
are likely to involve communication among different or-
gans, such as insulin-responsive skeletal muscle and WAT
(4,5). It has been proposed that adipose lipid storage
functions to prevent peripheral lipotoxicity (5). The exces-
sive lipid accumulation in skeletal muscle and liver leads to
insulin resistance resulting from the adverse effects of
chronic lipotoxicity on these tissues (5,6). Indeed, free fatty
acids (FFAs) can inhibit insulin activation of insulin re-
ceptor substrate-1–associated phosphatidylinositol-3-kinase
activity in skeletal muscle (7).
Studies have shown that the three peroxisome proliferator–
activated receptor isotypes (PPARa, b/d, and g) play central
roles in this process (8–10). PPARa activation decreases
dyslipidemia and regulates obesity in rodents by both in-
creasing hepatic FFA oxidation and decreasing levels of
circulating triglycerides responsible for adipocyte hyper-
trophy and hyperplasia (11,12). The transcriptional upre-
gulation of PPARg during adipogenesis is well studied.
Adipogenic hormones, such as glucocorticoids, cyclic
AMP, and insulin, induce a transient increase in the ex-
pression of the transcription factors CCAAT/enhancer-
binding protein (C/EBP) b and d early in adipocyte
differentiation. Together they induce PPARg expression
in preadipocytes, subsequently triggering full-blown adi-
pocyte differentiation (13). PPARb/d plays important func-
tions in adipose tissue metabolism, weight control, and
regulation of insulin sensitivity (14). PPARb/d protects
against weight gain, hypertriglyceridemia, and insulin re-
sistance in mice fed a high-fat diet (HFD) and in animals
that are genetically predisposed to obesity (15). Thus,
available information suggests that obesity and other fac-
ets of metabolic syndrome involve deregulation of signal-
ing pathways mediated by PPAR.
Transforming growth factor (TGF)-b1 signals through a
complex of two membrane-bound receptor serine/threonine
kinases that recruit and phosphorylate Smad2 and Smad3.
Once phosphorylated, Smad2 and Smad3 oligomerize with
Smad4 and translocate to the nucleus to participate in
transcriptional regulation (16). TGF-b1 has been reported
to inhibit adipogenesis, although these ﬁndings were de-
rived from in vitro preadipocyte models (17,18). Smad3
was shown to bind C/EBP and repress its transactivation
potential, thus abolishing the expression of PPARg2 (17).
However, the in vivo effect of Smad3 on adiposity remains
unclear. Elevated expression and plasma levels of TGF-b1
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have been reported in WAT from obese mice and in di-
abetic patients, respectively (19,20). TGFb1/Smad3 was
also shown to regulate insulin gene expression and pan-
creatic b-cell function (21). Conceivably, this will have an
impact on energy homeostasis. However, the effects of
Smad3 on communications among insulin-responsive or-
gans toward the development of diet-induced obesity and
type 2 diabetes have not been examined in vivo.
We show that Smad3-knockout (KO) mice have reduced
adiposity associated with impaired lipid accumulation and
adipogenesis. We revealed that this distinct phenotype
might be associated with altered expression of PPARg2
and b/d in the adipose tissue. Despite their reduced
physical activity arising from muscle atrophy, these KO
mice are resistant to HFD-induced obesity. The deﬁciency
of Smad3 also confers improved glucose tolerance and
insulin sensitivity.
RESEARCH DESIGN AND METHODS
Animals. Smad3 heterozygous mice on a C57BL/6 J background were inter-
crossed to produce Smad3-KO and wild-type (WT) offspring (22). Male mice of
the same age were used in all experiments.
Hyperinsulinemic-euglycemic clamp studies. Clamp studies were per-
formed as previously described (23).
In vitro insulin-induced glucose uptake assay. After fasting (15 h), tissues
were harvested, followed by incubation in a Krebs-Ringer bicarbonate buffer.
The solution was then replacedwith a Krebs-Ringer bicarbonate buffer solution
containing [3H]2-deoxyglucose (2.25 mCi/mL) and [14C] mannitol (0.3 mCi/mL)
in the presence or absence of insulin (12–14 nmol/L). The tissues were quickly
frozen until use. The tissues were lysed with 1 mol/L NaOH and centrifuged.
The supernatant was neutralized with 1 mol/L HCl, followed by measuring the
radioactivity for [3H]2-deoxyglucose and [14C] mannitol by a scintillation
counter. Net uptake of [3H]2-deoxyglucose uptake rates were corrected using
[14C] mannitol.
Real-time quantitative PCR. Quantitative PCR (qPCR) was performed on
three paired sets of WT and KO WAT. The sequences of the primer pairs are
summarized in Supplementary Table 1. qPCR was performed as previously
described (24).
Fatty acid uptake.WT and KO adipocytes were incubated in media containing
1 mCi/mL of [14C]palmitate complexed to BSA at a 6.6:1 molar ratio. The up-
take and accumulation of [14C]palmitate were measured using a scintillation
proximity assay (25).
Incorporation of [14C]palmitate into triglycerides.WT and KO adipocytes
were loaded with [14C]palmitate as described above. Lipids were extracted,
including a recovery standard in each sample (0.02 mCi of [3H]cholesterol),
and analyzed by thin-layer chromatography using hexane:ethyl ether:acetic
acid (80:20:1) as previously described (26).
Fatty acid oxidation in adipocytes. Substrate oxidation was monitored by
incubating cells with [14C]palmitate, with subsequent capture of liberated
14CO2 as previously described (25).
Lipolysis in adipocytes. Lipolysis was determined from freshly isolated
adipocytes by measurement of glycerol released into the medium as previously
described (27).
Lipid extraction from peripheral organs. Lipid was extracted from tissues
by a Folch extraction as previously described (28,29).
Statistical analysis. Statistical analysis was performed using two-tailed
Mann–Whitney tests. Values were expressed as mean 6 SEM. P , 0.05 was
considered statistically signiﬁcant. Detailed description of various methods
can be obtained from the corresponding author.
RESULTS
Smad3-KO mice exhibit reduced adiposity,
hypoglycemia, and hyperinsulinemia. Eight-week-old
Smad3-KO mice were characterized by reduced weight
and short body length when compared with WT mice (Fig.
1A and B). To identify the cause of these anomalies in KO
mice, we measured the weight of several organs,
expressed as percent body weight. The weights of the
liver, muscle, and brown adipose tissue were similar in WT
and KO mice (Supplementary Fig. 1A–C). WAT weight
from various fat pad depots was reduced by ;63% in KO
mice (Fig. 1C–E). Total body composition analysis by
quantitative nuclear magnetic resonance further conﬁrmed
that fat content in KO mice was reduced by ;63% (WT =
11.366 1.51% vs. KO = 4.186 0.29%; P, 0.05), whereas as
expected from this observation, the proportion of the lean
mass was consistently higher in KO mice (WT = 72.29 6
1.24% vs. KO = 80.01 6 0.49%; P , 0.01) (Fig. 1F). Smad3-
KO epididymal WAT contained smaller adipocytes than
their WT counterparts (WT = 2,206.03 6 153.08 mm2 vs.
KO = 567.49 6 34.11 mm2; P , 0.001) (Fig. 1G and H).
Fluorescence-activated cell sorting analysis comparing KO
and WT WAT using Nile Red staining revealed a smaller
and reduced number of adipocytes in KO mice (Fig. 1I and
J). No signiﬁcant difference in cell proliferation in WAT
and liver histology was observed for both genotypes
(Supplementary Fig. 1D and E).
Smad3-KO mice show increased peripheral insulin
sensitivity. To uncover the systemic manifestations of
reduced adiposity, we measured plasma lipid and glucose
parameters in WT and KO mice. Although the plasma tri-
glyceride level was elevated in KO mice, the FFA and
glycerol levels were reduced, suggesting decreased lipol-
ysis (Fig. 2A–C). Plasma cholesterol levels remained un-
changed (Supplementary Fig. 1F). KO mice displayed
hyperinsulinemia and were hypoglycemic regardless of
feeding status (Fig. 2D and E). KO mice exhibited signiﬁ-
cantly faster reduction in blood glucose concentration af-
ter glucose administration (Fig. 2F), and they were more
sensitive to insulin, as indicated by the prolongation of
blood glucose–lowering effects of insulin in these animals
(Fig. 2G).
These ﬁndings suggested that Smad3 deﬁciency im-
proved glucose tolerance and insulin responsiveness. To
understand the mechanisms of improved insulin sensitivity
in KO mice, the protein expression levels of key mediators
of insulin-signaling cascades were examined. Immunoblot
analysis of WAT and skeletal muscle revealed increased
GLUT4, insulin receptor substrate-1, phosphorylated
FoxO1, GSK-3b, Akt, and ERK expression in Smad3-KO
mice when compared with WT mice (Fig. 2H). Next, we
measured in vivo insulin-stimulated glucose uptake by
using hyperinsulinemic-euglycemic clamp studies. During
constant hyperinsulinemia, a higher glucose infusion rate
was required to maintain normal glucose levels in KO mice
compared with WT mice (Fig. 2I and J). To determine the
insulin-stimulated glucose uptake of skeletal muscle and
WAT, we assessed 2-deoxy-D-[1,2-3H]glucose (2-DG) up-
take during clamp studies. Whole-body glucose utilization
(peripheral insulin sensitivity) and percentage of insulin-
mediated suppression of hepatic glucose production (he-
patic insulin sensitivity) were signiﬁcantly increased in the
KO mice (Fig. 2K and L). We also found a signiﬁcant in-
crease of 2-DG uptake into the soleus, gastrocnemius
muscles, and WAT of KO mice (Fig. 2M). Data from in vitro
2-DG uptake of isolated soleus muscle and WAT were
congruent with the in vivo ﬁndings that KO mice are more
insulin-sensitive than WT (Fig. 2N and O).
Smad3-KO mice display decreased physical activity.
Next, we explored the impact of Smad3 deletion on whole-
body metabolic activity in the absence of a dietary chal-
lenge. To this end, mice were fed a standard chow diet,
and various metabolic parameters were monitored us-
ing metabolic cages. We observed no signiﬁcant differ-
ences in food and water consumption (Fig. 3A and B), O2
consumption (Fig. 3C), CO2 production (Fig. 3D), and
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metabolic rate (heat production) (Fig. 3E) between WT
and KO mice (Supplementary Fig. 2A–D). Both genotypes
consumed carbohydrates as the main energy source given
that their respiratory exchange ratio (RER), which equals
VO2/VCO2, was .0.92 (Fig. 3F). The RER indicates whether
carbohydrates (RER = 1.0) or lipids (RER = 0.7) are being
used to produce energy.
KO mice exhibited a decrease of ;74% in both horizontal
and rearing movements (Fig. 3G and H, Supplementary
Fig. 2E and F). Macroscopic comparison between WT and
KO showed a ;10% reduction in muscle ﬁber size (Fig. 3I
and J). Real-time qPCR analysis comparing WT and KO
muscle revealed no difference in the expression of genes
involved in b-oxidation or lipolysis (Fig. 3K).
The liver may contribute to the reduced adiposity in KO
mice via increased fatty acid (FA) b-oxidation. qPCR
analysis revealed no difference in mRNA expression level
of some genes involved in b-oxidation between WT and
KO liver (Supplementary Fig. 3A). In vitro total b-oxidation
assay also showed no signiﬁcant difference in the oxi-
dation of [14C]palmitate in KO and WT hepatocytes
(Supplementary Fig. 3B). These results indicate that the
reduced adiposity in KO mice did not stem from in-
creased energy expenditure arising from physical ac-
tivity or increased hepatic b-oxidation.
Smad3-KO mice show increased b-oxidation and
impaired lipolysis in WAT. Two factors contribute to
the expansion of WAT mass: increased size of existing
adipocytes because of fat accumulation and the formation
of new adipocytes through adipogenesis. Fat mass reﬂects
the ratio between lipogenesis and lipolysis/b-oxidation. To
examine the role of Smad3 in adipocyte physiology, we
performed focused qPCR array on WT and KO WAT. The
expression of several antiadipogenic factors, such as pre-
adipocyte factor 1 (Pref-1), cyclin D1, and C/EBP homol-
ogous protein 10 (CHOP-10), was elevated by twofold or
more in KO adipocytes, whereas there was a reduced
PPARg2 expression, suggesting that Smad3 deﬁciency
inhibits adipogenesis (Fig. 4A). PPARg2-regulated genes,
such as PEPCK and fatty acid synthase (FAS), were also
downregulated (Fig. 4A). The expression of the SREBP-1c,
which stimulates many genes involved in FA metabolism
and potentiates the transcriptional activity of PPARg2, was
decreased in KO mice. Furthermore, the expression of
FIG. 1. Reduced adiposity in Smad3-KO mice. A–E: Mean body weight (A), overall mouth-to-anus body length (B), and relative weight of sub-
cutaneous (C), epididymal (D), and visceral (E) white adipose fat pads of 8-week-old WT and Smad3-KO mice. Values represent percentage of
body weight; n = 8/group. F: Body fat content and lean mass composition analysis of WT and KO mice; n = 8/group. G: Representative hematoxylin–
eosin-stained parafﬁn-embedded section of WT and KO epididymal WAT. Scale bars, 100 mm. H: Mean cross-sectional area of WT and KO adi-
pocytes (n = 2,000/group). I: Mean adipocyte number in WT and KO epididymal WAT. J: Flow cytometry analysis of adipocytes (Nile Red positive)
and stromal/vascular cells (Hoechst positive) in WT and KO epididymal WAT. WAT was subjected to collagenase digestion. The adipocyte layer was
gently recovered and stained for 5 min with 10 mL of Nile Red staining solution (Molecular Probes, Eugene, OR). Cells positive for Nile Red were
counted using LSR II Flow Cytometer System (Becton Dickinson, Franklin Lakes, NJ). Data are represented as mean6 SEM. *P, 0.05, **P, 0.01,
***P , 0.001. (A high-quality color representation of this ﬁgure is available in the online issue.)
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FIG. 2. Smad3-KO mice develop hypoglycemia and insulin hypersensitivity. A–E: Mean plasma triglyceride (A), FFA (B), glycerol (C), blood
glucose (D), and blood insulin (E) in WT and KO mice. Blood glucose and insulin levels were measured at 6-h fasted and fed states. Blood glucose
levels were measured using an Accu-Chek Advantage glucometer with glucose measurement strips (Roche Diagnostics, Indianapolis, IN). Serum
insulin was measured by ELISA (Millipore, Billerica, MA). Serum total cholesterol, triglyceride, glycerol, and FFA concentrations were determined
by quantitative enzymatic assays using L-type CHO-H (Wako Pure Chemical Industries, Osaka, Japan), serum triglyceride determination kit
(Sigma-Aldrich, St. Louis, MO), free glycerol determination kit (Sigma-Aldrich), and serum/plasma FA and glycerol kit (Zen-Bio, Research Triangle
Park, NC), respectively. F: Changes in blood glucose concentration at the indicated time points after oral glucose tolerance test (OGTT).
G: Changes in blood glucose concentration at the indicated time points after IST. For the OGTT, mice were gavage fed with a 2 mg glucose/g body wt
glucose load. For the IST, mice fasted for 6 h were intraperitoneally injected with 0.75 mU insulin/g body wt using an insulin syringe. OGTT and IST
were performed on mice fasted for 6 h. Data are represented as mean 6 SEM, n = 8/group. H: Immunoblot analysis of indicated proteins in WT and
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diacylglycerol acyltransferase-1 and 2 was reduced by
approximately two- to threefold in KO WAT.
In contrast with lipogenesis, mobilization of fat stores
occurs predominantly through the hydrolysis of triglycerides
into glycerol and FAs. The expression of adipose triglyceride
lipase and hormone-sensitive lipase, the rate-limiting
enzymes of this process, were decreased by approximately
twofold in the KO WAT. Notably and in contrast with the
reduced expression of PPARg2, the expression of PPARb/
d in the KO WAT was signiﬁcantly increased. The mRNA
levels of PPARb/d-regulated genes, such as uncoupling
protein (UCP) 2, UCP3, and acyl-CoA oxidase 1 (14), were
KO skeletal muscle and WAT. b-Tubulin was used as loading and transfer control. Representative blots are shown. I and J: Hyperinsulinemic-
euglycemic clamp studies of Smad3-KO and WT mice. Glucose infusion rate required to maintained euglycemia in KO and WT mice (I). Blood
glucose levels during the clamp study (J). K: Whole-body glucose uptake (peripheral insulin sensitivity). L: insulin-mediated suppression of he-
patic glucose production rates (hepatic insulin sensitivity). Number represents percentage of suppression compared with basal hepatic glucose
output. M: 2-DG uptake by soleus, gastrocnemius muscles, and WAT of KO and WT mice during clamp studies. Data are represented as mean 6
SEM, n = 6/group. N and O: In vitro insulin-stimulated glucose uptake in skeletal muscles and WAT. 2-DG uptake into soleus muscle (N) and WAT
(O) was measured for 30 min. The tissues from WT and KO were incubated in the absence [insulin(2)] or presence of insulin [insulin(+), 14 nmol/
L], followed by measurement of 2-DG uptake. Net uptake of glucose was determined by subtracting the amount of [14C]mannitol from that of 2-DG.
Data represent mean 6 SEM, n = 10/group. *P , 0.05, **P , 0.01, ***P , 0.001 vs. WT controls.
FIG. 3. Smad3-KO mice exhibit reduced physical activity. A–D: The mean total food (A), water (B), O2 (C) consumptions, and CO2 emission (D)
during a 24-h light and dark cycle in WT and KO mice. Values in C and D were measured by indirect calorimetry and expressed as average VO2 and
VCO2 per kg body wt per h during a 24-h monitoring session of a light-dark cycle. E: Heat production of WT and KO mice was calculated from the O2
production and the RER and expressed as average kcal/h/kg body wt. F: Fuel consumption was determined from the ratio of CO2 emitted to the
amount of O2 consumed. Fuel type preference for carbohydrate has an RER of 1.0 versus fat of 0.7. G and H: Physical activity was assessed by the
number of horizontal and vertical beam breaks, which represent the total horizontal (G) and rearing (H) movements during the 24-h monitoring
period. I: Representative photograph showing the hind leg muscles of WT and KO mice. Small division on the ruler scale = 1 mm. J: Representative
hematoxylin–eosin-stained histologic section of the WT and KO quadriceps muscles. Scale bars, 100 mm. K: Relative fold change in mRNA level of
the indicated genes in WT and KO muscle was analyzed by real-time qPCR. Values were normalized to ribosomal protein L27. Results are rep-
resented as fold induction compared with WT. Primer sequences are summarized in Supplementary Table 1. Values represent mean 6 SEM, n =
8/group. *P , 0.05, **P , 0.01, ***P , 0.001. (A high-quality color representation of this ﬁgure is available in the online issue.)
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FIG. 4. Smad3-KO adipose tissues have increased FA uptake and b-oxidation. A: Relative fold change in mRNA level of the indicated genes in WT
and KO adipose tissue as determined by qPCR. Values are normalized to ribosomal protein L27. Normalized values from WT mice were arbitrarily
assigned a value of 1. Only genes with twofold or greater change in expression are presented. Values represent mean 6 SEM, n = 3/group. Primer
sequences are summarized in Supplementary Table 1. B: Immunoblot analysis of indicated proteins in WT and KO adipose tissues. b-Tubulin was
used as loading and transfer control. Representative blots from two mice for each genotype are shown. C–F: The rate of [14C]palmitate uptake (C),
[14C]palmitate incorporation into triglycerides (D), lipolysis (E), and [14C]palmitate oxidation (F) at the indicated time points of adipocytes
freshly isolated from the epididymal fat pads of WT and KO mice. Data are expressed as mean 6 SEM, n = 3/group. *P , 0.05, **P , 0.01, ***P ,
0.001 vs. WT controls.
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elevated in the KO WAT, suggesting an increase FA b-
oxidation and thermogenesis (Fig. 4A). The protein levels
of selected genes were similarly altered (Fig. 4B).
To strengthen the observations, we determined the ef-
fect of Smad3 deﬁciency on triglyceride metabolism. We
measured [14C]palmitate uptake and its conversion into
triglycerides in WT and KO adipocytes. We observed a 1.7-
fold increase in [14C]palmitate uptake in KO adipocytes
compared with WT (102.5 6 9.4 nmol/105 cells vs. 61.0 6
8.8 nmol/105 cells, respectively; Fig. 4C). Notably, the in-
creased FA uptake was not accompanied by a concomitant
increased conversion into triglycerides, which were re-
duced in KO adipocytes when compared with WT (0.26 6
0.11 nmol/105 cells vs. 0.49 6 0.17 nmol/105 cells, re-
spectively; Fig. 4D). We also assayed the levels of glycerol
released into the culture medium as an indicator of lipol-
ysis. Smad3 deﬁciency led to a twofold decrease in glyc-
erol release (WT = 2.9 6 0.74 nmol/105 cells vs. KO =
1.45 6 0.28 nmol/105 cells; Fig. 4E). We also found that the
oxidation of [14C]palmitate in KO adipocytes was twofold
higher than that of WT (0.61 6 0.09 nmol/105 cells vs.
0.33 6 0.08 nmol/105 cells, respectively; Fig. 4F). The in-
cubation of adipocytes with insulin reduced palmitate
oxidation in both WT and KO adipocytes; however, the
oxidation level in KO adipocytes remained 1.8-fold higher
than in WT (0.44 6 0.09 nmol/105 cells vs. 0.24 6 0.05
nmol/105 cells, respectively; Fig. 4F). Altogether, these
observations show that Smad3 deﬁciency impairs adipo-
genesis and in parallel moderates fat accumulation by
directing increased FA uptake to b-oxidation.
Repression of PPARb/d by C/EBPb is relieved on
upregulation of CHOP-10 resulting from Smad3
deﬁciency. C/EBPb represses the expression of PPARb/d
in keratinocytes (30). To gain insight into the regulation of
PPARb/d in adipocytes, we performed in vivo coimmuno-
precipitation and chromatin immunoprecipitation (ChIP)
using anti-C/EBPb antibodies in WT and KO mice (Fig. 5A).
ChIP and re-ChIP assays showed that in the WT WAT,
C/EBPb was associated with a speciﬁc C/EBP binding site
at 494–485 bp upstream from the PPARb/d promoter. The
data further showed that the association results in re-
cruitment to this element of a transcriptional repressor
complex containing histone deacetylase 1 (HDAC1) (Fig.
5B), indicating a C/EBPb-mediated repression of PPARb/d.
Notably, the association of C/EBPb-HDAC1 complexes with
this binding site was reduced in KO WAT (Fig. 5B). This
association was further conﬁrmed by qPCR normalized to
chromatin before immunoprecipitation (i.e., input) (Fig.
5C). No ampliﬁcation was observed using preimmune IgG
or a control DNA sequence (21179 to 2894).
Smad3 deﬁciency resulted in elevated expression of
CHOP-10 (Fig. 4B). We examined possible involvement of
CHOP-10 in the ability of C/EBPb to regulate PPARb/d
transcription. In vivo co-immunoprecipitation with anti-C/
EBPb followed by immunoblot with anti-CHOP-10 (Fig.
5A) revealed that the interactions between C/EBPb and
CHOP-10 are markedly enhanced in KO WAT (Fig. 5D).
Thus, increased C/EBPb-CHOP-10 interactions removed
the inhibitory effect of C/EBPb on PPARb/d promoter,
resulting in increased PPARb/d expression in KO mice
(Fig. 5E).
C/EBPb is closely involved in the regulation of PPARg
in adipocytes (31). As expected, ChIP assay involving the
PPARg2 promoter showed that C/EBPb was bound to the
C/EBP binding site. In contrast with the PPARb/d pro-
moter results, no ampliﬁcation was detected after re-ChIP
with anti-HDAC1 (Fig. 5B). In KO WAT, only weak ampli-
ﬁcation resulted with anti-C/EBPb (Fig. 5B). The increased
C/EBPb-CHOP-10 interactions in the KO when compared
with WT adipocytes (Fig. 5D) also diminished PPARg2
promoter activity (Fig. 5B). These observations show that
Smad3 deﬁciency alters adipose physiology, causing
a change associated with diminished PPARg2 and in-
creased PPARb/d expression (Fig. 5E).
Smad3-KO mice are resistant to HFD-induced obesity
and insulin resistance. A chronic HFD treatment induces
obesity and obesity-associated insulin resistance in mice
(32). To examine the effect of Smad3 deﬁciency on HFD-
induced obesity and insulin resistance, we placed KO and
WT mice on a low-fat diet (LFD) or HFD for 18 weeks. On
an HFD, WT mice became obese and were signiﬁcantly
heavier than those on an LFD (Fig. 6A and B). In contrast,
no signiﬁcant difference in body weight gain was observed
in KO mice on either diet, indicative of their resistance to
HFD-induced obesity (Fig. 6A and B). There was no dif-
ference in the mean daily food intake per mouse, regard-
less of diet, throughout the study (Supplementary Fig. 4A
and B).
As expected, HFD induced an increase in adipose mass
in all fat depots in WT mice (Fig. 6C and D). This increase
of 33% in WAT was associated with hypertrophy of adi-
pocytes (Fig. 6E and F) when compared with LFD con-
trols. No signiﬁcant difference in adipocyte size was
observed between KO mice on either diet (Fig. 6E and F).
Histologic analysis of the liver from WT mice on an HFD
showed macrovesicular hepatic steatosis as evidenced by
a fatty liver populated with abundant large vacuolar lipid
droplets (Fig. 6G). We also observed small lipid droplets in
the liver of WT mice on an LFD. Notably, the liver of KO
mice had few or no lipid droplets and did not develop
hepatic steatosis, regardless of treatment (Fig. 6G). HFD
induced an increase in triglyceride level in liver, skeletal
muscle, and pancreas of WT mice when compared with
LFD controls. No signiﬁcant difference in tissue tri-
glyceride level was observed between KO mice on either
diet (Fig. 6H–J, Supplementary Fig. 4C and D).
KO mice exhibited a higher plasma triglyceride level
compared with WT mice on an LFD (Fig. 7A). As expected,
the plasma triglyceride level was increased in WT and KO
mice on an HFD, with the former reaching a level com-
parable to that of the KO mice under an LFD (Fig. 7A). The
levels of glycerol and FFA were signiﬁcantly elevated in WT
and KO mice on an HFD (Fig. 7B and C), but remained
lower in KO mice on either diet. Similarly, regardless of the
diet and feeding status, KO mice consistently showed lower
blood glucose levels (Fig. 7D). No signiﬁcant difference
in plasma cholesterol level was detected (Supplementary
Fig. 4E). In agreement with these results, KO mice exhibited
higher insulin levels under an LFD, but in contrast with WT
mice, HFD treatment did not signiﬁcantly increase these
levels (Fig. 7E).
Glucose tolerance and insulin sensitivity tests (ISTs)
were carried out to determine the effects of an HFD on the
WT and KO mice. The blood glucose of WT mice on an HFD
only started to decrease at 45 min after glucose adminis-
tration and failed to return to the basal level even at the
120-min time point, indicative of impaired glucose toler-
ance in these diet-induced obese mice. By contrast, KO
mice under an HFD retained the rapid glucose clearance
ability as previously observed under the standard diet (Fig.
7F). In addition, HFD-induced obese WT mice also clearly
displayed obesity-associated insulin resistance (Fig. 7G),
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FIG. 5. Increased C/EBPb-CHOP-10 interaction in Smad3-KO adipocytes. A: Schematic outline of procedure for in vivo coimmunoprecipitation,
ChIP, and re-ChIP. B: DNA-protein complexes from WT or KO adipocytes were immunoprecipitated (ChIP) with anti-C/EBPb or preimmune IgG.
Enrichment of the DNA fragment containing the C/EBP binding site on the endogenous PPARb/d, PPARg2 promoter, or a control sequence up-
stream was evaluated by PCR. A second immunoprecipitation step (re-ChIP) was also performed with an anti-HDAC1-speciﬁc antibody (H).
I = input chromatin before immunoprecipitation,2 = negative control (without anti-HDAC1 antibody), M = DNA marker, IB = immunoblot. C: Real-
time qPCR was performed on immunoprecipitates of C/EBPb antibodies and normalized to input. Data are expressed as mean 6 SEM, n = 5/group.
***P , 0.001. D: Western blot analyses were also performed on proteins after immunoprecipitation with anti-C/EBPb antibody. Proteins were
separated by SDS-PAGE, blotted, and probed with anti-CHOP-10 primary antibody as indicated. Bands were detected by chemiluminescence.
Western blot control with b-tubulin antibody was performed using cell lysate before immunoprecipitation. E: Schematic diagram showing the
repression of PPARb/d by C/EBPb is relieved on upregulation of CHOP-10 resulting from depletion of Smad3.
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which was absent in KO mice. In vivo insulin-stimulated
glucose uptake by using hyperinsulinemic-euglycemic
clamp studies (Fig. 7H–J) and in vitro tissue-speciﬁc insulin-
stimulated 2-DG uptake (Fig. 7K and L) indicated that KO
mice were more tolerant to HFD-induced peripheral insulin
resistance compared with WT mice. In concordance, the
protein expression levels of indicated key mediators of
insulin-signaling cascades were elevated in the WAT and
skeletal muscle of HFD-fed KO mice (Fig. 7M). Altogether,
these observations indicated that KO mice are resistant to
HFD-induced obesity and numerous obesity-linked pathol-
ogies.
DISCUSSION
Obesity increases risk for type 2 diabetes, hypertension,
and cardiovascular diseases. Accordingly, much research
FIG. 6. Smad3-KO mice are resistant to HFD-induced obesity and hepatic steatosis. A and B: Graph shows mean body weight of WT and KO mice on
HFD or LFD over 18 weeks (A) and at the end of the 18-week diet regimen (B). C: Representative images of subcutaneous, epididymal, and visceral
adipose tissues, and the liver of WT and KO mice from the two diet regimens. Small division on the ruler scale = 1 mm. D: Mean weights of the liver
and the indicated adipose tissues of WT and KO mice after 18 weeks on HFD or LFD. Values are expressed as percentage of body weight.
E: Representative hematoxylin–eosin-stained histologic section of the WT and KO EAT after 18 weeks on HFD or LFD treatment. Scale bars, 100 mm.
F: Mean cross-sectional area of adipocytes (n = 400) from the WT and KOmice on the indicated diet regimen.G: Representative histologic section (oil
red O and methylene blue staining) of the liver tissues. Scale bars, 100 mm. White arrows indicate oil droplets. H–J: Quantiﬁcation of lipid accu-
mulation in peripheral organs. Total triglyceride extracted from fresh-frozen liver (H), skeletal muscle (I), and pancreas (J) of WT and KO mice fed
on HFD or LFD diet was expressed as amount in milimole per 1 g of protein. Data represent mean 6 SEM, n = 10/group. ##P , 0.01 vs. WT LFD
control; *P, 0.05, **P, 0.01, ***P, 0.001. EAT, epididymal adipose tissue; SAT, subcutaneous adipose tissue; VAT, visceral adipose tissue. (A high-
quality digital representation of this ﬁgure is available in the online issue.)
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FIG. 7. Smad3 deﬁciency ameliorates HFD-induced insulin resistance and glucose intolerance. A–E: The mean plasma triglyceride (A), FFA (B),
glycerol (C), blood glucose (D), and blood insulin (E) in WT and KO mice on HFD or LFD. Blood glucose and insulin levels were measured at 6-h
fasted and fed states. F: Changes in blood glucose concentration at the indicated time points after OGTT. G: Changes in blood glucose
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effort currently targets identiﬁcation of molecular targets
and the development of drugs that reduce fat mass and
improve insulin sensitivity. We examined the effect of
Smad3 deﬁciency on adiposity in mice. By using Smad3-
KO mice, we showed that Smad3 deﬁciency resulted in
decreased adiposity associated with improved glucose
tolerance and insulin responsiveness. Despite decreased
physical activity, Smad3-KO mice were resistant to HFD-
induced obesity. The deﬁciency in Smad3 also conferred
resistance to the development of obesity-associated glu-
cose intolerance, insulin resistance, and liver steatosis,
thus providing an insight into the role of Smad3 in the
pathogenesis of obesity and type 2 diabetes.
Previous in vitro studies showed that Smad3 inhibits the
transactivation potential of C/EBPs and consequently
abolishes the stimulation of the adipogenic master regu-
lator PPARg2 (17). In fact, an increase in adiposity might
be anticipated in the absence of the inhibitory effect of
Smad3 on C/EBPs, as in the case of Smad3 deﬁciency. We
found that Smad3-KO mice displayed decreased adiposity
resulting from reduced adipocyte number and size, sug-
gesting defective adipogenesis and altered lipid accumu-
lation. Gene expression proﬁling of the Smad3-KO WAT
revealed reduced expression of PPARg2 mRNA, with in-
creased expression of the preadipocyte-speciﬁc marker
Pref-1. PPARg2 not only participates in adipogenesis and
survival but also promotes lipid storage (33). Lipid accu-
mulation relies on lipogenesis, which involves de novo
synthesis of FA and glycerol, FA uptake, and synthesis of
triglycerides. Notably, the expression of rate-limiting en-
zymes involved in these processes, such as FAS, PEPCK, and
diacylglycerol acyltransferase, was downregulated in the
Smad3-KO WAT (34). The reduced lipogenesis is exacer-
bated by concomitant downregulation of enzymes partici-
pating in the pentose phosphate pathway required for de
novo synthesis of biomolecules. Lending support, knockout
or adipose-speciﬁc deletion of some examined genes in
mice has resulted in similar phenotypic features in Smad3-
KO mice. Pref-1-null mice, for instance, display obesity and
increased serum lipid metabolites (35). Adipose-speciﬁc
knockout of PEPCK results in a fraction of mice developing
lipodystrophy (36). As a central enzyme in lipogenesis, FAS
has been identiﬁed as a candidate gene for determining
body fat (37). Smad3 deﬁciency also resulted in increased
FA b-oxidation as evidenced by the reduced plasma FFA
level, offering another plausible explanation for the reduced
adipocyte size in the Smad3-KO mice. Altogether, these
ﬁndings indicate that Smad3 deﬁciency leads to impaired
adipogenesis and lipogenesis in mice.
It has been proposed that adipose lipid storage functions
to prevent peripheral lipotoxicity (5). Particularly evident
in HFD-induced obesity, the chronic accumulation of FFA
in skeletal muscles and liver eventually dampens their in-
sulin responsiveness (5,7). Indeed, the ablation of PPARg2
in obese mouse models results in reduced fat mass but
leads to severe insulin resistance, b-cell failure, and dys-
lipidemia because of deposition of toxic reactive lipid
species in the peripheral organs (38). However, this
reported insulin resistance and b-cell failure were not
observed in the Smad3-KO mice, which also exhibited re-
duced expression of adipose PPARg2. This outcome may
partly be the result of elevated plasma insulin levels and
insulin hypersensitivity, which caused hypoglycemia in
these mice. Indeed, our results also revealed enhanced in-
sulin responsiveness in peripheral organs, such as skeletal
muscle and WAT. Insulin activation of phosphatidylinositol-
3-kinase/protein kinase B (PKB) (Akt) can inhibit TGF-b1
signaling via the formation of a PKB-Smad3 complex. This
interaction does not inhibit PKB activity, but inhibits Smad3-
mediated gene regulation (39,40). A recent study showed
that Smad3 occupies the insulin gene promoter to repress its
expression and increases glucose-stimulated insulin secre-
tion because of enhanced insulin signaling in b-cell islets
(21). Furthermore, the expression of adipocytokines, such
as visfatin and resistin, can inﬂuence glucose uptake and
metabolism (41). An increase in glucose uptake and gly-
colysis with the effects of these adipocytokines and a de-
creased plasma FFA level as observed in the Smad3-KO
mice may partially contribute to the improved glucose tol-
erance and enhanced insulin sensitivity in these animals.
Altogether, these ﬁndings place Smad3-PKB at a point of
convergence in the crosstalk between TGF-b/Smad3 and
insulin signaling pathways and provide insights into their
roles in the development of obesity and insulin resistance.
Our ﬁndings that Smad3-KO mice displayed increased
insulin-stimulated whole-body (peripheral insulin sensitiv-
ity) and tissue-speciﬁc (skeletal muscle and WAT) glucose
uptake underscored the relevance of this crosstalk in vivo.
The skeletal muscle is the largest energy consumer in
mice and plays an important role in lowering plasma FFA
and glycerol (42,43); however, we found that Smad3-KO
mice exhibited reduced physical activity associated with
muscular atrophy, in concordance with a role of Smad3 in
b2-adrenergic–induced muscle hypertrophy (44). Thus, it is
unlikely that increased energy expenditure in the skeletal
muscles could account for the reduced adiposity in these
mice. Although adipose tissue is not a major energy con-
sumer compared with the skeletal muscle, increased
b-oxidation in WAT can have a profound impact on adi-
posity and insulin sensitivity (41). Comparative gene ex-
pression analysis of WT and Smad3-KO WAT revealed
upregulation of PPARb/d, UCP2, UCP3, and acyl-CoA ox-
idase 1, all of which are involved in energy dissipation and
peroxisomal FA oxidation. The activation of PPARb/d in
obese mice has been shown to selectively induce expres-
sion of an array of genes required for adipose FA catabolism
and thermogenesis but not genes involved in lipogenesis and
fat storage, which are controlled by PPARg2 (14). Metabolic
rate remained unchanged in Smad3-KO mice, reﬂecting a
balance between reduced skeletal muscle activity and in-
creased adipose lipid oxidation. Many regulatory mechanisms
may inﬂuence the expression of PPARg and PPARb/d in
adipocytes. The relative proportion of homodimeric or het-
erodimeric C/EBP is likely to play important role. Although
concentration at the indicated time points after IST. OGTT and IST were performed on mice fasted for 6 h on an 18-week LFD or HFD regimen.
Data represent mean 6 SEM, n = 10/group. H–J: Hyperinsulinemic-euglycemic clamp studies of Smad3-KO and WT mice. Glucose infusion rate
required to maintained euglycemia in KO and WT mice (H); whole-body glucose uptake (peripheral insulin sensitivity) (I); 2-DG uptake by soleus,
gastrocnemius muscles, and WAT of HFD-fed KO and WT mice during clamp studies (J). Data are represented as mean6 SEM, n = 5/group. K–L: In
vitro insulin-stimulated glucose uptake in skeletal muscles and WAT. 2-DG uptake into soleus muscle (K) and WAT (L) was measured for 30 min.
The tissues from WT and KO were incubated in the absence [insulin(-)] or presence of insulin [insulin(+), 14 nmol/L], followed by measurement of
2-DG uptake. Net uptake of glucose was determined by subtracting the amount of [14C]mannitol from that of 2-DG. Data represent mean 6 SEM,
n = 6/group. *P , 0.05, **P , 0.01, ***P , 0.001 vs. WT controls. M: Immunoblot analysis of indicated proteins from skeletal muscle and WAT of
HFD-fed WT and KO mice. b-Tubulin was used as loading and transfer control. Representative blots are shown.
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it is essential for PPARg2 expression, C/EBPb inhibits
PPARb/d promoter activity. CHOP-10, which exhibited el-
evated expression in Smad3-KO WAT, acts as a dominant-
negative inhibitor of C/EBP by preventing its binding to
DNA (45); this function adds to the complexity of regu-
lating the expression of these two PPAR isotypes with
apparent opposing functions in the adipocyte. The reason
for the differential regulation is unclear but may be at-
tributed to different promoter context. The functional AP-1
site driving induction of the PPARb/d promoter is in close
proximity to the identiﬁed C/EBP binding region. Smad3
may interact with c-JUN (AP-1), inhibiting c-JUN activity
that is necessary for AP-1–stimulated PPARb/d expression,
as reported in keratinocytes (46).
In summary, we have found that Smad3 is a multifaceted
regulator in glucose and lipid metabolism, as well as in the
pathogenesis of obesity and type 2 diabetes, thus identi-
fying Smad3 as a potential target for the treatment of
obesity and its associated disorders.
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